Cannabis Rescheduling: History and Current Status in the UK

From Prohibition to Prescription: The Journey to Rescheduling

• Cannabis was originally placed in Schedule 1 in 1971, preventing any medical use
• Advisory Council on the Misuse of Drugs recommended rescheduling in 2018
• The November 2018 rescheduling moved cannabis-based medicines to Schedule 2
• The trigger was high-profile cases including Alfie Dingley and Billy Caldwell

The rescheduling of cannabis-based medicinal products in November 2018 was a watershed moment for UK medical cannabis policy. It followed years of advocacy by patient families, medical professionals, and campaigners, and represented a significant departure from the long-standing position that cannabis had no accepted medical use. Understanding this history helps contextualise the regulatory framework that governs prescribing today.

The 2018 Rescheduling: What Changed and What Did Not

• Only specified cannabis-based medicines moved to Schedule 2 — cannabis itself remains Class B
• NHS prescribing remained tightly restricted to a small number of licensed indications
• Private prescribing pathways opened up significantly for a broader range of conditions
• The rescheduling did not create a legal framework for recreational use

The 2018 rescheduling was targeted rather than comprehensive. It created a legal route for specialist clinicians to prescribe cannabis-based medicines on a named-patient basis, but it did not fundamentally change the controlled drug status of cannabis as a substance. The practical result was a two-tier system: a small NHS pathway for the most severe cases, and a larger private clinic sector serving a much wider patient population.

Advisory Council on the Misuse of Drugs Ongoing Review

• The ACMD continues to advise government on the appropriate scheduling of controlled substances
• Further rescheduling to Schedule 4 has been discussed in academic and policy circles
• ACMD recommendations are not binding but carry significant weight in policy decisions
• Industry and patient groups actively engage with ACMD consultations

The Advisory Council on the Misuse of Drugs remains the principal scientific and advisory body on drug scheduling in the UK. Its recommendations have historically been influential, though governments have occasionally chosen not to follow them. Ongoing engagement with ACMD processes is an important part of the medical cannabis industry’s regulatory affairs strategy.

What Further Rescheduling Could Mean for the Industry

• Schedule 4 classification would reduce some administrative burdens around prescribing
• Prescription requirements and record-keeping obligations would be simplified
• Reduced barriers could increase prescribing volumes and patient access
• Any change would require primary or secondary legislation and public consultation

The prospect of further rescheduling is a recurring topic within UK medical cannabis policy circles. Proponents argue that the current Schedule 2 requirements create unnecessary administrative burdens that deter prescribing. Opponents caution that robust controls are appropriate given the evolving evidence base. The industry’s interests are best served by engaging constructively with this debate through evidence-based advocacy.